Skip to content
Back to meeting Original
Medthority· @Medthority · X·· 2 days agoScore70

DELLPHI-304

Body

#ESMO26
Extended follow-up from the phase 3 DeLLphi-304 trial showed durable survival benefit with tarlatamab in previously treated #SCLC.
📊 Median OS: 13.6 vs 8.4 months
📊 38% lower risk of death
Presented by @charlesrudin
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX

32 views · 0 likes · 0 reposts · 0 replies

Source: Medthority · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.